Recruiting Studies
Advanced SearchData: ClinicalTrials.gov · Source of record for eligibility and locations
Top Cities for Mantle Cell Lymphoma Clinical Trials
Mantle Cell Lymphoma clinical trials are recruiting across 54 cities. Here are the cities with the most active studies:
Mantle Cell Lymphoma Trial Phases
16 research organizations are sponsoring mantle cell lymphoma trials.
About Mantle Cell Lymphoma
Mantle cell lymphoma (MCL) is a rare, aggressive type of non-Hodgkin lymphoma that develops from B-cells in the mantle zone of lymph nodes. It accounts for about 5-7% of all NHL cases. Treatment includes combination chemotherapy, targeted therapy, and stem cell transplant.
Clinical trials are advancing new treatments for mantle cell lymphoma. Currently, 23 studies are recruiting a combined 1,965 participants across the United States. Research is being conducted by 16 organizations including Alliance for Clinical Trials in Oncology, BeiGene, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company and 13 others.
2026 Mantle Cell Lymphoma Research Landscape
As of July 2026, the mantle cell lymphoma clinical trial landscape includes 23 actively recruiting studies across 54 cities in the United States. These studies are collectively seeking 1,965 participants, with an average enrollment target of 85 per study.
The research spans multiple phases of development: 17 studies are in PHASE2, 7 studies are in PHASE1, 3 studies are in PHASE3. The presence of Phase 3 trials indicates that some mantle cell lymphoma treatments are in late-stage testing and may be approaching regulatory review.
Research is being led by 16 different organizations, including Alliance for Clinical Trials in Oncology, BeiGene, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, Hoffmann-La Roche, Academic and Community Cancer Research United, and 11 others. The large number of sponsors reflects significant research interest and investment in mantle cell lymphoma treatment advancement.
Geographically, mantle cell lymphoma trials are most concentrated in Duarte, California (9 trials); Irvine, California (3 trials); Houston, Texas (3 trials); Los Angeles, California (2 trials); New Haven, Connecticut (2 trials) and 7 other cities.
Featured Mantle Cell Lymphoma Studies
Highlighted recruiting studies for mantle cell lymphoma, selected by enrollment size and research scope.
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (previously untreated). Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Zanubrutinib may stop the growt...
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma
The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib versus zanubrutinib plus placebo.
A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
The purpose of this study is to understand the long-term safety and effectiveness of lisocabtagene maraleucel (liso-cel) for the treatment of Mantle Cell Lymphoma (MCL).
Frequently Asked Questions About Mantle Cell Lymphoma Clinical Trials
Are there mantle cell lymphoma clinical trials near me?
Yes, there are 23 mantle cell lymphoma clinical trials currently recruiting across 54+ cities in the United States, including Duarte, California; Irvine, California; Houston, Texas. Browse the studies above to find one at a location convenient for you.
How do I join a mantle cell lymphoma clinical trial?
To join a mantle cell lymphoma clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are mantle cell lymphoma clinical trials free?
Yes, participation in mantle cell lymphoma clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of mantle cell lymphoma treatments are being studied?
Current mantle cell lymphoma clinical trials are testing a range of approaches across PHASE2 (17 studies), PHASE1 (7 studies), PHASE3 (3 studies). These include new drugs, combination therapies, medical devices, and other interventions sponsored by 16 research organizations.
Is it safe to participate in mantle cell lymphoma clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated July 16, 2026 from ClinicalTrials.gov
About This Data
Data: ClinicalTrials.gov · Source of record for eligibility and locations
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated July 16, 2026 · Data from ClinicalTrials.gov